Published in Curr Opin Oncol on November 01, 2008
Potential therapeutic benefits of strategies directed to mitochondria. Antioxid Redox Signal (2010) 1.40
Changing paradigms in the treatment of multiple myeloma. Haematologica (2009) 0.87
Lenalidomide, melphalan, and prednisone association is an effective salvage therapy in relapsed plasma cell leukaemia. J Oncol (2009) 0.84
Thalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myeloma. Ann Hematol (2011) 0.84
Early relapse after single auto-SCT for multiple myeloma is a major predictor of survival in the era of novel agents. Bone Marrow Transplant (2014) 0.81
Thalidomide decreases gelatinase production by malignant B lymphoid cell lines through disruption of multiple integrin-mediated signaling pathways. Haematologica (2009) 0.79
Quality of life assessment in multiple myeloma patients undergoing dose-reduced tandem autologous stem cell transplantation. Mediterr J Hematol Infect Dis (2011) 0.79
Initial cytoreductive treatment with thalidomide plus bolus vincristine/doxorubicin and reduced dexamethasone followed by autologous stem cell transplantation for multiple myeloma. Invest New Drugs (2009) 0.76
Novel drugs for the treatment of multiple myeloma. Haematologica (2010) 0.75
Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med (2013) 6.21
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med (2014) 5.08
Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol (2008) 2.30
Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. J Clin Oncol (2011) 2.27
Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol (2008) 2.09
Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. J Clin Oncol (2013) 1.79
Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood (2011) 1.75
Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy. J Clin Oncol (2008) 1.53
The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma. Br J Haematol (2008) 1.52
Hematopoietic stem cell transplantation for multiple myeloma beyond 2010. Blood (2010) 1.52
The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade. Biol Blood Marrow Transplant (2011) 1.45
Lymphoplasmacytic lymphoma causing light chain cast nephropathy. Nephrol Dial Transplant (2012) 1.45
[Guidelines for the use of bisphosphonates in multiple myeloma: Recommendations of the expert committee of the Spanish Myeloma Group from the PETHEMA group]. Med Clin (Barc) (2009) 1.40
Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations. J Clin Oncol (2009) 1.32
Emergence of oligoclonal bands in patients with multiple myeloma in complete remission after induction chemotherapy: association with the use of novel agents. Haematologica (2010) 1.14
Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients. Biol Blood Marrow Transplant (2007) 1.06
Impact of MiRSNPs on survival and progression in patients with multiple myeloma undergoing autologous stem cell transplantation. Clin Cancer Res (2012) 1.05
Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents. Cytokine (2008) 1.04
Extramedullary involvement in multiple myeloma. Haematologica (2012) 1.03
Complications of multiple myeloma. Hematol Oncol Clin North Am (2007) 1.03
Natural history and prognostic impact of oligoclonal humoral response in patients with multiple myeloma after autologous stem cell transplantation: long-term results from a single institution. Haematologica (2013) 0.94
Renal, hematologic and infectious complications in multiple myeloma. Best Pract Res Clin Haematol (2005) 0.92
Clinical applicability and prognostic significance of molecular response assessed by fluorescent-PCR of immunoglobulin genes in multiple myeloma. Results from a GEM/PETHEMA study. Br J Haematol (2013) 0.91
Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study. Haematologica (2010) 0.90
Smoldering multiple myeloma and monoclonal gammopathy of undetermined significance. Curr Treat Options Oncol (2006) 0.89
Bortezomib: a valuable new antineoplastic strategy in multiple myeloma. Acta Oncol (2005) 0.89
Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients. Br J Haematol (2013) 0.88
Fatal immune hemolytic anemia following allogeneic stem cell transplantation: report of 2 cases and review of literature. Transfus Med Rev (2013) 0.87
Changing paradigms in the treatment of multiple myeloma. Haematologica (2009) 0.87
Impact on response and survival of DNA repair single nucleotide polymorphisms in relapsed or refractory multiple myeloma patients treated with thalidomide. Leuk Res (2011) 0.84
Multiparameter flow cytometry evaluation of plasma cell DNA content and proliferation in 595 transplant-eligible patients with myeloma included in the Spanish GEM2000 and GEM2005<65y trials. Am J Pathol (2012) 0.84
Spontaneous rupture of the spleen as immediate complication in autologous transplantation for primary systemic amyloidosis. Eur J Haematol (2008) 0.83
Prognostic impact of serum immunoglobulin heavy/light chain ratio in patients with multiple myeloma in complete remission after autologous stem cell transplantation. Biol Blood Marrow Transplant (2012) 0.82
Limitations of Gallium-67 SPECT in histological transformation of chronic lymphocytic leukaemia: an analysis of 13 patients with clinically suspected Richter's syndrome. Br J Haematol (2002) 0.81
Acquired Fanconi syndrome secondary to monoclonal gammopathies: a case series from a single center. Clin Lymphoma Myeloma Leuk (2013) 0.81
Extensive soft-tissue involvement by plasmablastic myeloma arising from displaced humeral fractures. Eur J Haematol (2010) 0.81
Bortezomib/dexamethasone followed by autologous stem cell transplantation as front line treatment for light-chain deposition disease. Eur J Haematol (2012) 0.81
Differential humoral responses against heat-shock proteins after autologous stem cell transplantation in multiple myeloma. Ann Hematol (2013) 0.81
Long-term results of thalidomide in refractory and relapsed multiple myeloma with emphasis on response duration. Eur J Haematol (2006) 0.80
Impact of global and gene-specific DNA methylation pattern in relapsed multiple myeloma patients treated with bortezomib. Leuk Res (2013) 0.80
Moving forward in myeloma research. Haematologica (2004) 0.79
Incorporating monoclonal antibodies into the therapy of multiple myeloma. J Clin Oncol (2012) 0.78
Refining "total therapy" for myeloma. Blood (2010) 0.78
Multiple myeloma in serologic complete remission after autologous stem cell transplantation: impact of bone marrow plasma cell assessment by conventional morphology on disease progression. Biol Blood Marrow Transplant (2011) 0.77
Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma. Br J Haematol (2013) 0.76
Are all myelomas preceded by MGUS? Blood (2009) 0.75
How to treat multiple myeloma: thoughts on a multicentre survey in Germany. Onkologie (2010) 0.75
Aminoglycoside-associated severe renal failure in patients with multiple myeloma treated with thalidomide. Leuk Lymphoma (2004) 0.75
Novel drugs for the treatment of multiple myeloma. Haematologica (2010) 0.75
Thalidomide: a step forward in the treatment of malignant monoclonal gammopathies. Clin Lymphoma (2003) 0.75
Interleukin 6 and tumour necrosis factor alpha serum levels in monoclonal gammopathy of undetermined significance. Br J Haematol (2002) 0.75
Appropriateness of applying the response criteria for multiple myeloma to Waldenstrom's macroglobulinemia? Semin Oncol (2003) 0.75